(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
SF Chinatown's historic Empress of China building being revived into cultural campus - 2Gulf aluminum output tumbles on Iran war
- 32024 Ferrari Roma With Just One Owner & 3,300 Miles For Sale At $...
- 4Allow Innovative Progressions To have a Massive Effect
- 5Artemis moon mission breaks record for distance from Earth
- Instructions to Pick the Ideal SUV Size for Seniors
- Europe could get 42 more days of summer by the year 2100 due to climate change
- Bennu asteroid samples provide clues about solar system origins and 'space gum'
- International issues on the agenda as Frances's Macron visits China
- Vote In favor of Your Favored Kind Of Tea
- Three arrested in Paris after attempted bomb attack outside Bank of America
- It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
- 6 Nations for Setting up camp
- Instructions to Back Your Sunlight powered chargers: Tracking down Possible Choices
